Testosterone Cypionate: Complete Clinical Guide for TRT

What Testosterone Cypionate Is and How It Works

Testosterone cypionate is a long-chain ester of testosterone dissolved in cottonseed oil. After intramuscular or subcutaneous injection, esterases in the tissue and bloodstream cleave the cypionate side chain, releasing free testosterone into circulation. The cypionate ester slows that release compared to unesterified testosterone, producing a pharmacokinetic curve that peaks at roughly 24 to 72 hours post-injection and declines over the following 5 to 12 days.

The hormone itself is identical to endogenous testosterone. Once free in the blood, it binds androgen receptors in skeletal muscle, bone, brain, and genital tissue, and a fraction converts via aromatase to estradiol. That estradiol is not incidental: it contributes to libido, bone density maintenance, and cardiovascular lipid regulation in men. Suppression of estradiol with aggressive aromatase-inhibitor use is one of the more common clinical errors in TRT management.

The FDA first approved testosterone cypionate (Depo-Testosterone) in 1979. The package insert lists primary and secondary hypogonadism as approved indications. It is classified as a DEA Schedule III controlled substance, meaning prescriptions cannot be phoned in or auto-refilled beyond five refills in six months. Learn more about the FDA label here.

Who Qualifies for Testosterone Cypionate

The American Urological Association 2018 guideline states that TRT should be offered to men with consistent symptoms of hypogonadism and a confirmed total testosterone below 300 ng/dL on at least two separate morning measurements. AUA 2018 Testosterone Deficiency Guideline.

Symptoms that prompt testing include decreased libido, erectile dysfunction, depressed mood, fatigue, reduced muscle mass, and increased adiposity. A single low testosterone value is not sufficient for diagnosis, because testosterone follows a diurnal rhythm that drops roughly 35% between 8 AM and 4 PM and varies day to day. Brambilla et al., 2009, Clin Endocrinol.

Absolute contraindications include breast cancer, prostate cancer (active), hematocrit above 54%, untreated severe obstructive sleep apnea, and desire for fertility preservation without adjunct therapy. Men who want to maintain fertility should discuss concurrent human chorionic gonadotropin (hCG) at 500, 1 to 000 IU two to three times per week, which preserves intratesticular testosterone and spermatogenesis during exogenous androgen use. Hsieh et al., 2013, J Urol.

Standard Dosing Protocols for Testosterone Cypionate

Dosing is individualized, but published protocols from major endocrinology societies provide starting ranges. The Endocrine Society's 2018 clinical practice guideline recommends 75 to 100 mg intramuscularly per week or 150 to 200 mg every two weeks for testosterone cypionate. Endocrine Society 2018 Hypogonadism Guideline.

Every-two-week injections produce wide peak-to-trough swings: serum testosterone may reach 1,200, 1 to 500 ng/dL on day three and fall below 300 ng/dL by day thirteen. Many patients report energy crashes and mood dips in the final days before their next injection. Weekly injections narrow that swing substantially. Splitting a two-week dose into twice-weekly or every-3.5-day subcutaneous injections narrows it further, producing levels that resemble the pharmacokinetics of shorter esters while retaining cypionate's lower injection frequency relative to propionate.

Subcutaneous (SQ) administration in the abdominal fat or lateral thigh is not an FDA-labeled route, but peer-reviewed data support its efficacy and tolerability. A 2012 study by Spratt et al. in the Journal of Clinical Endocrinology and Metabolism found SQ testosterone cypionate 50 to 100 mg weekly achieved target serum levels with injection-site reactions no more frequent than IM. Spratt et al., 2012, JCEM.

A practical starting protocol for most men:

• Week 1, 6 (titration): 50 mg SQ or IM twice weekly (100 mg total per week)
• Lab check at week 6: Draw trough testosterone (morning of next scheduled injection), hematocrit, and estradiol (sensitive assay)
• Adjustment: Target trough 500 to 700 ng/dL. Increase by 10 to 20 mg per injection if trough is below 400 ng/dL; reduce if above 800 ng/dL or hematocrit exceeds 52%

Men on every-two-week protocols should have their trough drawn on day 13 or 14 before injection.

Testosterone Cypionate vs. Testosterone Enanthate

These two esters are pharmacologically close. Cypionate has a half-life of approximately 8 days; enanthate sits at approximately 4.5 days. Both are dissolved in oil and administered IM or SQ. Neither is clinically superior for symptom relief or serum testosterone targets in head-to-head use, because the active molecule is identical once the ester is cleaved. Testosterone pharmacokinetics review, Bhasin et al., 2010, NEJM.

Practical differences:

• Availability. Testosterone cypionate is the dominant formulation in the United States. Enanthate is more commonly used in Europe and is the basis for most European prescribing guidelines.
• Carrier oil. Cypionate typically uses cottonseed oil; enanthate often uses sesame oil. Men with cottonseed or sesame allergies should specify the alternative.
• Injection frequency. Enanthate's slightly shorter half-life makes twice-weekly dosing somewhat more common in European protocols, though cypionate is frequently used the same way in US practice.
• Cost. Both are available as generics at comparable prices, typically $30, $80 per 10 mL vial at major US pharmacies.

For most American patients starting TRT, cypionate is the default because supply chains and clinical familiarity favor it. Switching between the two at equivalent total weekly doses rarely produces detectable clinical differences.

Testosterone Cypionate vs. Testosterone Propionate

Testosterone propionate has a half-life of roughly 2 days, requiring injections every 1 to 3 days to maintain stable serum levels. That frequency makes it poorly suited for standard TRT and is the reason it has largely been replaced by longer esters in clinical practice.

The short half-life does offer one advantage: in men who experience side effects (elevated hematocrit, mood changes), serum levels fall more quickly after stopping. A 2019 review in Andrology noted propionate's primary contemporary TRT role is in men needing rapid dose adjustment or those in whom very fine-grained titration is clinically warranted. Morgentaler et al., 2015, Mayo Clin Proc (propionate context).

For the majority of men, cypionate or enanthate offers a better quality-of-life profile because fewer injections per week are required to maintain physiologic testosterone levels.

Testosterone Cypionate vs. Testosterone Pellets

Subcutaneous pellets (brand name Testopel) are implanted in the buttock or lateral hip under local anesthesia, typically every 3 to 6 months. Each pellet contains 75 mg of crystalline testosterone. Most men receive 8, 12 pellets per session, delivering 600 to 900 mg of testosterone in a single procedure.

Advantages of pellets include the elimination of weekly injections and avoidance of transference risk (which is relevant for fathers of young children using topical products). Disadvantages include the invasive nature of implantation, inability to adjust dose quickly if side effects emerge, and cost: pellet insertion typically runs $300, $600 per procedure without insurance and is not universally covered.

A 2015 study in the Journal of Sexual Medicine (N=130) found pellet therapy produced mean serum testosterone of 613 ng/dL at three months with high patient satisfaction scores, but 5.6% of patients required pellet extrusion due to infection or extrusion. Pastuszak et al., 2015, J Sex Med.

Testosterone cypionate offers faster titration and lower per-dose cost. Pellets suit men who have stable dosing established and strongly prefer a hands-off administration schedule.

Testosterone Cypionate vs. Testosterone Gel (AndroGel)

Topical testosterone gels, including AndroGel 1% and 1.62%, Testim, and Vogelxo, deliver testosterone transdermally. AndroGel 1.62% at 40.5 mg per day produces mean serum testosterone in the normal range in approximately 66% of hypogonadal men. FDA label, AndroGel 1.62%.

Gels eliminate injections entirely, which is a meaningful benefit for men with needle aversion. However, several clinical drawbacks are documented:

• Transference. Direct skin-to-skin contact can transfer testosterone to partners and children. The FDA added a black-box warning for this in 2009. FDA Drug Safety Communication, 2009.
• Absorption variability. Serum levels vary significantly by body-site application, sweating, showering timing, and skin thickness. Roughly 10 to 15% of men are poor absorbers and never reach target levels on gel.
• Cost. Brand-name gels run $200, $500 per month; generic testosterone gel is available at lower cost but still exceeds injectable cypionate on a per-milligram basis.
• DHT elevation. Topical application increases dihydrotestosterone (DHT) more than injections do, because testosterone is converted to DHT in the skin. Some men on gel report accelerated scalp hair thinning.

Testosterone cypionate produces more predictable serum concentrations than gel and costs significantly less. For men who cannot tolerate injections, gel remains a valid first-line option, but cypionate is generally preferred when injection is feasible.

Side Effects and Risk Management

Common side effects of testosterone cypionate are dose-dependent and manageable with appropriate monitoring.

Erythrocytosis (elevated hematocrit). The most clinically significant hematologic risk. Testosterone stimulates erythropoiesis through erythropoietin and direct bone marrow effects. A 2014 meta-analysis of 58 randomized controlled trials (N=3,876) found testosterone therapy increased hematocrit by a mean of 3.2 percentage points versus placebo. Calof et al., 2005, J Gerontol. Hematocrit above 54% significantly increases blood viscosity and venous thromboembolism risk; dose reduction, extended injection intervals, or therapeutic phlebotomy are the standard responses.

Estradiol elevation. Aromatization of testosterone to estradiol rises proportionally with testosterone dose. Estradiol above 50, 60 pg/mL on a sensitive assay may contribute to nipple sensitivity, water retention, or mood effects in some men. Aromatase inhibitors such as anastrozole 0.25 to 0.5 mg twice weekly are sometimes added, but their use should be judicious because low estradiol causes bone density loss and worsens lipid profiles. Finkelstein et al., 2013, NEJM.

Testicular atrophy and infertility. Exogenous testosterone suppresses LH and FSH via negative pituitary feedback, reducing intratesticular testosterone production and spermatogenesis. Testicular volume may decrease noticeably within 3 to 6 months. For men concerned about fertility, hCG co-administration largely prevents this; a prospective study by Coviello et al. found 500 IU hCG every other day maintained intratesticular testosterone within the normal range during exogenous testosterone administration. Coviello et al., 2005, JCEM.

Acne and oily skin. Androgen stimulation of sebaceous glands increases sebum production. Topical benzoyl peroxide 5% or low-dose doxycycline 40 mg/day may be needed in men with significant acne.

Sleep apnea. Testosterone can worsen upper-airway obstruction in predisposed men. A baseline Epworth Sleepiness Scale assessment and referral for polysomnography should accompany TRT initiation in obese patients or those with snoring history.

Cardiovascular considerations. The TRAVERSE trial (N=5,246, median follow-up 33 months) found that testosterone therapy in men with hypogonadism and elevated cardiovascular risk did not increase major adverse cardiovascular events (MACE) compared to placebo (hazard ratio 1.07 to 95% CI 0.94, 1.21). However, non-fatal atrial fibrillation occurred more frequently in the testosterone arm (HR 1.35 to 95% CI 1.06, 1.73). Lincoff et al., NEJM 2023. Men with known arrhythmias or paroxysmal atrial fibrillation should discuss this signal with their cardiologist before starting TRT.

Monitoring Schedule on Testosterone Cypionate

Consistent follow-up is what separates safe TRT from unsupervised use. The following schedule aligns with Endocrine Society and AUA guidance:

Baseline (before first injection):

• Total testosterone (two separate morning draws)
• Free testosterone (calculated or equilibrium dialysis)
• LH, FSH (to classify primary vs. secondary hypogonadism)
• Hematocrit and complete blood count
• PSA (men 40 and older)
• Comprehensive metabolic panel
• Lipid panel
• Estradiol (sensitive LC-MS/MS assay preferred)

At 6 weeks (first trough draw):

• Total testosterone (trough, morning of next injection)
• Hematocrit
• Estradiol if symptomatic

At 3 months:

• Total testosterone, hematocrit, PSA
• Dose adjustment if indicated

Every 6 to 12 months thereafter:

• Full panel as at baseline
• DRE in men 50 and older or 40 and older with risk factors

The Endocrine Society guideline states: "We suggest measuring testosterone levels to confirm the adequacy of therapy, and we recommend against using testosterone concentrations as the sole driver of clinical decisions." This reflects the importance of symptom response alongside lab values. Endocrine Society, Bhasin et al., JCEM 2018.

Injection Technique: Intramuscular vs. Subcutaneous

Intramuscular (IM). The ventrogluteal site (palm placed on the greater trochanter, index finger toward anterior superior iliac spine, injection in the V between index and middle fingers) is preferred over the dorsogluteal because it avoids the sciatic nerve and produces more consistent absorption. A 23-gauge, 1-inch needle is adequate for most men. Draw with an 18-gauge needle, then switch to 23-gauge for injection to avoid pushing through small-gauge needles.

Subcutaneous (SQ). A 27- or 28-gauge, 0.5-inch insulin needle works well. Inject at a 45-degree angle into the pinched skin of the lower abdomen (at least 2 inches from the navel) or lateral thigh. Volumes above 0.5 mL SQ may cause discomfort; this is one reason twice-weekly dosing (0.25 to 0.5 mL per injection) is preferred over single weekly SQ injections when using high-concentration 200 mg/mL vials.

Rotating sites between right and left sides each injection reduces nodule formation. Warming the vial briefly in a pocket or warm water reduces oil viscosity and makes injection easier, particularly in cold environments.

Starting Testosterone Cypionate Through Telehealth

The DEA's 2023 telemedicine regulations, finalized following the COVID-19 public health emergency, allow prescribing of controlled substances via telehealth only if the prescriber has conducted a proper evaluation. For Schedule III testosterone prescriptions, that evaluation must include documented symptom review, lab confirmation of low testosterone, and a clinical risk-benefit discussion. DEA Telemedicine Rules 2023.

A compliant telehealth TRT visit should include:

1. Review of two confirmed morning testosterone labs below 300 ng/dL
2. Symptom questionnaire (ADAM or AMS scale)
3. Review of hematocrit, PSA, and cardiovascular history
4. Documented discussion of fertility implications and contraindications
5. State-specific prescribing compliance (some states require in-person evaluation for Schedule III substances)

Lab draws can be ordered through national patient-service centers (Quest, LabCorp) with a provider-issued requisition. HealthRX providers review results typically within 24, 48 business hours and generate a prescription when criteria are met.

How Long Before Testosterone Cypionate Works

Symptom response follows a predictable timeline, though individual variation is real.

• Libido and energy: 3 to 6 weeks. These tend to be early responders.
• Mood and cognitive clarity: 3 to 12 weeks. Some men notice changes within days; others take several months.
• Erectile function: 6 to 12 weeks. Testosterone supports nitric oxide synthesis and penile smooth muscle health but does not uniformly resolve ED, particularly when vascular disease contributes.
• Body composition (muscle gain, fat loss): 3 to 6 months. Changes are modest without resistance training; a 2001 RCT by Bhasin et al. (N=61) showed testosterone increased fat-free mass by 6.1 kg over 20 weeks in eugonadal men with resistance exercise, but gains in hypogonadal men starting from a deficit are generally greater. Bhasin et al., 2001, NEJM.
• Bone density: 12 to 24 months. DXA changes are not typically apparent at 6-month scans.

Men who see no symptomatic improvement after 3 to 6 months at confirmed target serum levels should be evaluated for other contributing conditions: sleep apnea, thyroid dysfunction, depression, and relationship factors all independently affect libido, energy, and mood.

Confirm trough testosterone is consistently above 400 ng/dL before concluding the therapy is inadequate. A trough of 280 ng/dL on a twice-weekly protocol means the dose or frequency needs adjustment, not that testosterone therapy does not work for that patient.